2024
Validation of a whole slide image management system for metabolic‐associated steatohepatitis for clinical trials
Pulaski H, Mehta S, Manigat L, Kaufman S, Hou H, Nalbantoglu I, Zhang X, Curl E, Taliano R, Kim T, Torbenson M, Glickman J, Resnick M, Patel N, Taylor C, Bedossa P, Montalto M, Beck A, Wack K. Validation of a whole slide image management system for metabolic‐associated steatohepatitis for clinical trials. The Journal Of Pathology Clinical Research 2024, 10: e12395. PMID: 39294925, PMCID: PMC11410674, DOI: 10.1002/2056-4538.12395.Peer-Reviewed Original ResearchMeSH KeywordsBiopsyClinical Trials as TopicHumansImage Interpretation, Computer-AssistedLiverNon-alcoholic Fatty Liver DiseaseObserver VariationReproducibility of ResultsConceptsClinical trialsAssessment of disease activityOverall percent agreementLiver biopsyDisease activityPathological assessmentWashout periodHistological assessmentEndpoint assessmentGold standardPercent agreementScoring systemExpert pathologistsSteatohepatitisAverage agreementDigital scoresPathologistsTrials
2018
The impact of diet‐induced hepatic steatosis in a murine model of hepatic ischemia/reperfusion injury
Liss KHH, McCommis KS, Chambers KT, Pietka TA, Schweitzer GG, Park SL, Nalbantoglu I, Weinheimer CJ, Hall AM, Finck BN. The impact of diet‐induced hepatic steatosis in a murine model of hepatic ischemia/reperfusion injury. Liver Transplantation 2018, 24: 908-921. PMID: 29729104, PMCID: PMC6097916, DOI: 10.1002/lt.25189.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsDiet, WesternDisease Models, AnimalHumansLiverLiver Function TestsLiver TransplantationMaleMiceMice, Inbred C57BLNon-alcoholic Fatty Liver DiseaseObesityReperfusion InjuryTissue and Organ HarvestingConceptsDiet-induced hepatic steatosisSteatotic liversHepatic steatosisReperfusion injuryLiver diseaseMicrovesicular steatosisMurine modelObesity-associated nonalcoholic fatty liver diseaseHepatic ischemia/reperfusion injuryEnd-stage liver diseaseIschemia/reperfusion injuryNonalcoholic fatty liver diseasePlasma alanine aminotransferase levelsAlanine aminotransferase levelsFatty liver diseaseCriteria donor organsInflammatory cytokine concentrationsPotential therapeutic approachHepatic IRISteatotic graftsLiver transplantationAminotransferase levelsCommon indicationNonalcoholic steatohepatitisOrgan failure
2017
Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis
McCommis KS, Hodges WT, Brunt EM, Nalbantoglu I, McDonald WG, Holley C, Fujiwara H, Schaffer JE, Colca JR, Finck BN. Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis. Hepatology 2017, 65: 1543-1556. PMID: 28027586, PMCID: PMC5397348, DOI: 10.1002/hep.29025.Peer-Reviewed Original ResearchConceptsStellate cell activationPeroxisome proliferator-activated receptor γProliferator-activated receptor γNonalcoholic steatohepatitisMitochondrial pyruvate carrier 2Cell activationRodent modelsReceptor γDevelopment of NASHNonalcoholic fatty liver diseaseDose-limiting side effectHepatic stellate cell activationFatty liver diseaseInsulin-sensitizing thiazolidinedionesLiver of miceLiver-specific deletionExpression of markersTrans fatty acidsMetabolic syndromeLiver diseaseHepatocyte dysfunctionHepatic fibrosisLiver fibrosisPharmacologic developmentMouse model
2014
Role of liver biopsy in nonalcoholic fatty liver disease.
Nalbantoglu I, Brunt E. Role of liver biopsy in nonalcoholic fatty liver disease. World Journal Of Gastroenterology 2014, 20: 9026-37. PMID: 25083076, PMCID: PMC4112884, DOI: 10.3748/wjg.v20.i27.9026.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonalcoholic fatty liver diseaseFatty liver diseaseLiver diseaseLiver biopsyPediatric nonalcoholic fatty liver diseaseNASH Clinical Research NetworkLocation of fibrosisSpecific histologic lesionsCardiovascular risk factorsExcess alcohol intakeChronic liver diseaseClinical Research NetworkClinical research trialsLiver biopsy evaluationLimitations of biopsyNon-invasive testingImportant liver diseaseHepatic manifestationNecroinflammatory activityMetabolic syndromeAlcohol intakeHistologic findingsHepatic triglyceridesRisk factorsBiopsy evaluation